All posts by: Michael Zand

Editorial Article: T Cell Engineering for Breakthrough Immunotherapy Research – SelectScience

SelectScienceEditorial Article: T Cell Engineering for Breakthrough Immunotherapy ResearchSelectScienceThe adoptive transfer of T cells expressing genetically engineered chimeric antigen receptors (CARs) has shown great potential in the treatment of ce… Continue reading

Stem cell therapy for chronic bladder ischaemia – Nature.com

Stem cell therapy for chronic bladder ischaemiaNature.comIn a rat model of atherosclerosis-induced chronic bladder ischaemia, bladder overactivity could be improved by human amniotic-fluid-derived stem cell (hAFSC) treatment. Following arterial balloon… Continue reading

Seed Company Secures CRISPR Rights – whotv.com

Unlikely new problem emerges for immunotherapy trials – The Pharma Letter (registration)

The Pharma Letter (registration)Unlikely new problem emerges for immunotherapy trialsThe Pharma Letter (registration)Given the prevalence of cancer, not having enough patients to test the potential cancer treatments of tomorrow might seem an unlikely p… Continue reading

Defining the Future of the Stem Cell Industry – Interviews with Stem Cell Industry Executives – Research and Markets – Business Wire (press release)

TMR Research Blog (press release) (blog)Defining the Future of the Stem Cell Industry – Interviews with Stem Cell Industry Executives – Research and MarketsBusiness Wire (press release)Stem cell research has been in process for over five decades. Stem … Continue reading

Ryboquin raises £1.8m for drug development in gene therapy – Drug Target Review